Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
First Claim
1. A method of monitoring efficacy of a treatment of a diabetes or pre-diabetes condition in a subject, comprising:
- measuring binding of a plurality of lectins to a first sample from the subject;
administering a treatment to the subject;
measuring binding of the plurality of lectins to a second sample from the subject after administering the treatment to the subject; and
comparing the binding of the plurality of lectins to the first sample to the binding of the plurality of lectins to the second sample,wherein the plurality of lectins comprises Aleuria aurantia lectin, Concanavalin A, Phaseolus vulgaris agglutinin, Datura stramonium lectin, and Sambucus nigra lectin; and
wherein a decrease in the binding of each of the plurality of lectins to the second sample relative to the binding of each of the plurality of lectins to the first sample indicates that the treatment is effective, and/or wherein an increase in the binding of each of the plurality of lectins to the second sample relative to the binding of each of the plurality of lectins to the first sample indicates that the treatment is ineffective.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid.
56 Citations
14 Claims
-
1. A method of monitoring efficacy of a treatment of a diabetes or pre-diabetes condition in a subject, comprising:
-
measuring binding of a plurality of lectins to a first sample from the subject; administering a treatment to the subject; measuring binding of the plurality of lectins to a second sample from the subject after administering the treatment to the subject; and comparing the binding of the plurality of lectins to the first sample to the binding of the plurality of lectins to the second sample, wherein the plurality of lectins comprises Aleuria aurantia lectin, Concanavalin A, Phaseolus vulgaris agglutinin, Datura stramonium lectin, and Sambucus nigra lectin; and wherein a decrease in the binding of each of the plurality of lectins to the second sample relative to the binding of each of the plurality of lectins to the first sample indicates that the treatment is effective, and/or wherein an increase in the binding of each of the plurality of lectins to the second sample relative to the binding of each of the plurality of lectins to the first sample indicates that the treatment is ineffective. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
Specification